Novel targeted therapies for Parkinson’s disease

Molecular Medicine

Theodora Ntetsika¹  Ioanna Markaki¹  Paraskevi-Evita Papathoma² 

[1] Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden;Center of Neurology, Academic Specialist Center, Solnavägen 1E, 113 65, Stockholm, Sweden;Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden;Department of Neurology, Danderyd Hospital Stockholm, Stockholm, Sweden;

关键词: Parkinson’s disease;    Therapeutics;    Drug development;   

DOI  :  10.1186/s10020-021-00279-2

来源: Springer

【 摘 要 】

Parkinson’s disease (PD) is the second more common neurodegenerative disease with increasing incidence worldwide associated to the population ageing. Despite increasing awareness and significant research advancements, treatment options comprise dopamine repleting, symptomatic therapies that have significantly increased quality of life and life expectancy, but no therapies that halt or reverse disease progression, which remain a great, unmet goal in PD research. Large biomarker development programs are undertaken to identify disease signatures that will improve patient selection and outcome measures in clinical trials. In this review, we summarize PD-related mechanisms that can serve as targets of therapeutic interventions aiming to slow or modify disease progression, as well as previous and ongoing clinical trials in each field, and discuss future perspectives.

【 授权许可】

CC BY